Fibrocell Science (FCSC) Trading -7.5% Higher

Fibrocell Science Inc (NASDAQ:FCSC) traded up 7.5% on Tuesday . The company traded as high as $2.42 and last traded at $2.21. 23,909 shares traded hands during mid-day trading, a decline of 88% from the average session volume of 198,573 shares. The stock had previously closed at $2.39.

A number of equities research analysts recently weighed in on the company. Zacks Investment Research cut Fibrocell Science from a “hold” rating to a “sell” rating in a report on Tuesday, September 18th. HC Wainwright set a $22.00 target price on Fibrocell Science and gave the company a “buy” rating in a report on Thursday, August 9th. Finally, ValuEngine upgraded Fibrocell Science from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd.

The firm has a market cap of $21.51 million, a P/E ratio of -0.28 and a beta of 0.69.

Fibrocell Science (NASDAQ:FCSC) last announced its earnings results on Thursday, August 9th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.50). equities research analysts forecast that Fibrocell Science Inc will post -3.31 earnings per share for the current year.

A hedge fund recently raised its stake in Fibrocell Science stock. Point72 Asset Management L.P. raised its stake in shares of Fibrocell Science Inc (NASDAQ:FCSC) by 100.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 400,000 shares of the company’s stock after buying an additional 200,000 shares during the quarter. Point72 Asset Management L.P. owned about 1.41% of Fibrocell Science worth $236,000 at the end of the most recent reporting period. 25.79% of the stock is currently owned by institutional investors.

About Fibrocell Science (NASDAQ:FCSC)

Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.

See Also: What is the Ex-Dividend Date in Investing?

Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with's FREE daily email newsletter.

Leave a Reply